drugset
drugset / Trial / NCT06226571

A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

NCT06226571 ↗

Phase 1 Active not recruiting 76 enrolled Syndax Pharmaceuticals
NaSequentialOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of SNDX-5613 in combination with intensive chemotherapy in participants with newly diagnosed acute myeloid leukemia (AML) harboring alterations in KMT2A, NPM1, or NUP98 genes.

Timeline

Start
2024-05-21
Primary completion
2027-02
Completion
2027-02

Drugs

EvaluationDrugModalityDoseRoute
Subject SNDX-5613 Unknown — Oral
Background Cytarabine Small molecule — Intravenous
Background Daunorubicin Small molecule — Intravenous
Background Idarubicin Small molecule — Intravenous

Indications

acute myeloid leukemia